Philippines - English - FDA (Food And Drug Administration)

comark international corporation - povidone-iodine - cleanser - 7.5%

Philippines - English - FDA (Food And Drug Administration)

cymar international inc.; distributor: comark international corporation - povidone-iodine - topical solution - 10 mg/ml (10% w/v)

Singapore - English - HSA (Health Sciences Authority)

mandarin opto-medic co pte ltd - ophthalmology - the femto ldv femtosecond surgical laser is an ophthalmic surgical laser indicated for use in the creation of a corneal flap in patients undergoing lasik surgery or other treatment requiring initial lamellar resection of the cornea.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

ipharma (pty) ltd - ophthalmic solution - not indicated - each 1 ml solution contains latanoprost 50,0 mcg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

ipharma (pty) ltd - ophthalmic solution - not indicated - each 1,0 ml contains latanoprost 50,0 ╡g and timolol maleate equivalent to timolol 5,0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

grc surgical pty ltd - 40808 - marker, lesion localization, implantable - the hydromark breast biopsy site marker is made of a resorbable hydrogel that expands with fluid and is then resorbed. the hydrogel material is visible under ultrasound. embedded in the hydrogel is a coiled metallic wire made of stainless steel or titanium that will be permanently visible under x-ray and mri when the hydrogel is resorbed. the marker is supplied pre-loaded in a rigid applicator. to mark tissue during a percutaneous breast biopsy procedure, be visible under ultrasound for at least 6 weeks, and be permanently visible by x-ray and mri. the hydromark breast biopsy site marker is made of a resorbable hydrogel that expands with fluid and is then resorbed. the hydrogel material is visible under ultrasound. embedded in the hydrogel is a coiled metallic wire that will be permanently visible under x-ray and mri when the hydrogel is resorbed. the marker is supplied pre-loaded in delivery systems designed to fit a number of probes and handpieces.

Australia - English - Department of Health (Therapeutic Goods Administration)

grc surgical pty ltd - 40808 - marker, lesion localization, implantable - the hydromark breast biopsy site marker is made of a resorbable hydrogel that expands with fluid and is then resorbed. the hydrogel material is visible under ultrasound. embedded in the hydrogel is a coiled metallic wire made of stainless steel or titanium that will be permanently visible under x-ray and mri when the hydrogel is resorbed. the marker is supplied pre-loaded in a flexible applicator. to mark tissue during a percutaneous breast biopsy procedure, be visible under ultrasound for at least 6 weeks, and be permanently visible by x-ray and mri. the hydromark breast biopsy site marker is made of a resorbable hydrogel that expands with fluid and is then resorbed. the hydrogel material is visible under ultrasound. embedded in the hydrogel is a coiled metallic wire that will be permanently visible under x-ray and mri when the hydrogel is resorbed. the marker is supplied pre-loaded in delivery systems designed to fit a number of probes and handpieces.

Australia - English - Department of Health (Therapeutic Goods Administration)

proteomics international pty ltd - ct287 - clinical chemistry ivds - promarkerd captsure? elisa is an in vitro quantitative test intended for the detection of three protein biomarkers (analytes) in human plasma. this quantitative test result together with three clinical variables are intended to enter into an algorithm (promarkerd hub) to generate the prognosis and diagnosis risk scores of diabetic kidney disease (dkd) in patients with type 2 diabetes. the test is designed to be used by clinical laboratory trained personal.

Australia - English - Department of Health (Therapeutic Goods Administration)

proteomics international pty ltd - ct287 - clinical chemistry ivds - promarkerd (ms) is an in vitro quantitative test intended for the detection of three protein biomarkers (analytes) in human plasma. this quantitative test result together with three clinical variables are intended to enter into an algorithm (promarkerd hub) to generate the prognosis and diagnosis risk scores of diabetic kidney disease (dkd) in patients with type 2 diabetes. the test is designed to be used by clinical laboratory trained personal.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

akzo nobel pty limited - copper present as cuprous thiocyanate; zinc pyrithione - paint - copper present as cuprous thiocyanate cyanide active 125.0 g/l; zinc pyrithione mineral-zinc active 50.0 g/l - antifouling - boat - aluminium | aluminium boat - marine growth | barnacles | fresh-water fouling organisms | marine fouling organisms | mussels